Clinical trials: Plasmodium Vivax Malaria
Plasmodium Infection
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria…
- Trial name
- NCT05117567
- Testing
- Personal protection package
- Volunteers
- 5,868 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Vivax
Serological Screen and Treat Trial for Plasmodium Vivax
This is a clinical trial to evaluate an experimental serological diagnostic technique intended to identify people at high risk of having dormant malaria parasites in their liver.
- Trial name
- SSAT (NCT04223674)
- Testing
- Serological screen and treat
- Where
- Indonesia
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Healthy Lactating Women
Tafenoquine and Primaquine in Colostrum and Breast Milk
Each year almost a million infants are born small for gestational age due to malaria infection in pregnancy. These infants are at risk for stillbirth or neonatal death, and being born too small predisposes the survivors to…
- Trial name
- TBM (NCT04984759)
- Testing
- Primaquine, Tafenoquine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Oxford
MALARIA, FEVER
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
The study is a randomized open label clinical trial to verify the reproducibility of a sporozoite challenge model for Plasmodium vivax in humans.
- Conditions
- MALARIA, FEVER, Sweating Fever, Chills
- Trial name
- NCT00367380
- Testing
- 413ABM, 414WRR, 418JAL
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria
Papua New Guinean Duffy Negativity And Vivax Malar
The purpose of this study is to learn more about vivax malaria in very young children, how the growth of children is affected by malaria infections, and how inherited traits protect children from getting malaria.
- Trial name
- NCT00138489
- Where
- Papua New Guinea
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar
In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of…
- Trial name
- NCT04695886
- Testing
- Community-delivered Integrated Malaria Elimination (CIME) intervention model
- Volunteers
- 6,440 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Vivax
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
A clinical trial aimed to standardize a vivax sporozoite infection model in human volunteers was conducted at the Malaria Vaccine and Drug Development Center (MVDC) in collaboration with the Immunology Institute at Valle State…
- Trial name
- ChallengeII (NCT01083095)
- Testing
- Sporozoite Challenge Model for Plasmodium vivax in Humans
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
SB-252263 (Tafenoquine, TQ) is an 8-aminoquinoline (8-AQ) antimalarial drug being developed by GlaxoSmithKline (GSK), the U.S. Army Medical Research and Materiel Command (USAMRMC) and Medicines for Malaria Venture (MMV).
- Trial name
- NCT01205178
- Testing
- Chloroquine, Primaquine, Tafenoquine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Malaria Prevention Cambodia
Trial of monthly DHA-piperaquine for malaria prevention in health volunteers.
- Trial name
- MPC (NCT01624337)
- Testing
- DHA-piperaquine
- Where
- Cambodia
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Malaria
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
Background: The World Health Organization recommends that antimalarial treatment policies be evaluated every few years to check their efficacy. P.
- Trial name
- NCT02043652
- Testing
- Chloroquine, Primaquine
- Where
- Brazil
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
This study assesses the effectiveness and feasibility of enhanced reactive case detection (RACD) targeting high-risk villages and forest workers for reducing Plasmodium falciparum and Plasmodium vivax transmission in southern Lao…
- Trial name
- COMBAT (NCT04416945)
- Testing
- Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up
- Where
- Laos
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria Vaccine
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the…
- Trial name
- NCT07831226
- Testing
- LYB014 low dose, LYB014 high dose, LYB017 low dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Falciparum, Plasmodium Vivax Malaria
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
This study, conducted at Johns Hopkins University Center for Immunization Research in Washington DC, will test the safety and immune response of healthy volunteers to two experimental malaria vaccines.
- Trial name
- NCT00295581
- Testing
- PpPfs25/ISA51 & ScPvs25/ISA51
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Pharmacokinetics in Healthy Volunteers
Postpartum 8-aminoquinoline Breast Milk Study
In Papua New Guinea, administration of primaquine (PQ) or tafenoquine (TQ) to breastfeeding mothers is contraindicated during the first six months postpartum, when infants are recommended to be exclusively breastfed, because of a…
- Trial name
- NCT07060404
- Testing
- Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
- Where
- Papua New Guinea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Curtin University
Malaria
Prevention of P. Vivax Malaria During Pregnancy in Bolivia
The purpose of this study is to determine which, between weekly prophylaxis or malaria attack treatment, both by chloroquine, is the most appropriate way to protect women and foetus from P.
- Trial name
- NCT00290420
- Testing
- Chloroquine profilaxis
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Plasmodium Vivax Infection
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through experimental injection of cryopreserved P.
- Trial name
- MIST2 (NCT05071079)
- Testing
- An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria Falciparum, Malaria Vivax
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent. This was a Phase I, single-centre, multi-component, double-blind, randomised, placebo-controlled study in healthy male and female…
- Conditions
- Malaria Falciparum, Malaria Vivax, Healthy Volunteers
- Trial name
- NCT00928083
- Testing
- OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture